Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)

Phase 2

Conditions: Rheumatoid Arthritis

Interventions: Drug: Bredinin tablet 150mg
Drug: Bredinin tablet 50mg

First Posted Date: 2013-12-09

Last Posted Date: 2015-06-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT02005757

Locations: 🇰🇷
Eulji University Hospital, Daejeon, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷
Kangwon National University Hospital, Kangwon, Korea, Republic of

and more 4 locations

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

Phase 1

Completed

Conditions: Liver Dysfunction

Interventions: Drug: CKD-501

First Posted Date: 2013-12-09

Last Posted Date: 2016-07-04

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 26

Registration Number: NCT02005744

Locations: 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of

Drug-drug Interaction Study(Lobeglitazone, Warfarin)

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Lobeglitazone
Drug: Warfarin

First Posted Date: 2013-12-06

Last Posted Date: 2014-07-03

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT02002611

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

Phase 3

Conditions: Hypertension

Interventions: Drug: TELMINUVO Tab. (80/2.5mg)
Drug: S-amlodipine 2.5mg
Drug: TELMINUVO Tab. (80/5mg)
Drug: S-amlodipine 5mg

First Posted Date: 2013-11-14

Last Posted Date: 2013-11-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 200

Registration Number: NCT01983735

Locations: 🇰🇷
The catholic university of Korea Seoul St. Mary's hospital, Seoul, Korea, Republic of

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Phase 3

Conditions: Mixed Hyperlipidemia

Interventions: Drug: Atorvastatin 20mg
Other: Placebo (Fenofibrate 160 mg)
Drug: Fenofibrate 160mg

First Posted Date: 2013-10-08

Last Posted Date: 2015-02-04

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 476

Registration Number: NCT01956201

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of

and more 27 locations

Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg

Not Applicable

Completed

Conditions: Immunosuppression

Interventions: Drug: Tacrobell capsule 1mg
Drug: Prograf capsule 1mg

First Posted Date: 2013-07-29

Last Posted Date: 2014-07-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 50

Registration Number: NCT01910077

Locations: 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

Phase 4

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: Newrabell® Tablet 10mg

First Posted Date: 2013-05-22

Last Posted Date: 2015-09-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 39

Registration Number: NCT01860482

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Gwangju, Hwasun-eup,Hwasun-gun, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju, Donggu, Jebongro, Korea, Republic of

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine

Phase 1

Completed

Conditions: Essential Hypertension
Hyperlipidemia

Interventions: Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Drug: Telmisartan 80mg and S-amlodipine 5mg

First Posted Date: 2013-04-29

Last Posted Date: 2013-08-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01842230

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.

Phase 1

Completed

Conditions: Essential Hypertension
Hyperlipidemia

Interventions: Drug: Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg
Drug: atorvastatin 40mg

First Posted Date: 2013-04-29

Last Posted Date: 2013-08-01

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01842256

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Mycophenolate Mofetil 250mg
Drug: Mycophenolate Mofetil 500mg

First Posted Date: 2013-04-29

Last Posted Date: 2015-08-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 156

Registration Number: NCT01842269

Locations: 🇰🇷
Kandong Sacred Heart Hospital, Seoul, Korea, Republic of
🇰🇷
Chunbuk National University Hospital, Chonju, Korea, Republic of
🇰🇷
Wonkwang University School of Medical & Hospital, Iksan, Korea, Republic of

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy